Security
Biogen Inc. Common Stock · BIIB
BIIBNASDAQCommon stockCurrentCIK 875045Updated Oct 29, 2026
Name history
BIOGEN IDEC INC. · through Mar 20, 2015BIOGEN IDEC INC · through Apr 25, 2007IDEC PHARMACEUTICALS CORP / DE · through Nov 12, 2003IDEC PHARMACEUTICALS CORP / CA · through Feb 14, 1997
BIIB price & chart
Loading TradingView…
NASDAQ:BIIB on TradingView ↗About the company
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, Instagram, LinkedIn, X, YouTube.
In the news
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB ↗
Seeking Alpha
Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growth ↗
Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive ↗
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript ↗
SEC disclosures
BIOGEN INC. files 8-K: Material Event ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 29,207,500,000Source | 28,313,200,000Source | 28,193,200,000Source | 28,330,200,000Source | 26,804,100,000Source | 29,483,100,000Source | 28,033,100,000Source | 26,567,600,000Source | 29,439,500,000Source | 28,049,300,000Source | 26,844,800,000Source | 24,554,100,000Source |
| Property, Plant and Equipment, NetUSD | 3,075,700,000Source | 3,210,900,000Source | 3,301,600,000Source | 3,098,800,000Source | 3,249,300,000Source | 3,017,900,000Source | 3,132,400,000Source | 3,275,300,000Source | 3,055,400,000Source | 3,181,300,000Source | 3,309,700,000Source | 3,298,600,000Source |
| GoodwillUSD | 6,490,700,000Source | 6,485,800,000Source | 6,807,500,000Source | 6,493,100,000Source | 6,227,400,000Source | 6,488,700,000Source | 6,477,100,000Source | 6,227,400,000Source | 6,491,100,000Source | 6,478,900,000Source | 6,219,200,000Source | 5,749,000,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 9,331,900,000Source | 9,805,500,000Source | 7,344,600,000Source | 9,467,500,000Source | 8,232,900,000Source | 9,053,500,000Source | 9,584,600,000Source | 8,284,700,000Source | 9,178,500,000Source | 9,691,200,000Source | 8,363,000,000Source | 1,850,100,000Source |
| Current assets: | ||||||||||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | 1,342,400,000Source | 1,404,800,000Source | 1,664,100,000Source | 1,705,000,000Source |
| Inventory, NetUSD | 2,209,400,000Source | 2,469,200,000Source | 2,982,400,000Source | 2,274,300,000Source | 2,506,100,000Source | 1,949,000,000Source | 2,273,900,000Source | 2,516,800,000Source | 2,168,100,000Source | 2,460,500,000Source | 2,527,400,000Source | 1,344,400,000Source |
| Assets, CurrentUSD | 8,936,600,000Source | 6,830,500,000Source | 8,454,100,000Source | 7,967,700,000Source | 7,108,500,000Source | 9,190,400,000Source | 7,626,000,000Source | 6,756,200,000Source | 8,974,100,000Source | 7,456,800,000Source | 6,859,300,000Source | 9,791,200,000Source |
| Operating Lease, Right-of-Use AssetUSD | 330,500,000Source | 380,400,000Source | 460,900,000Source | 334,500,000Source | 389,400,000Source | 251,300,000Source | 346,400,000Source | 428,100,000Source | 265,400,000Source | 356,400,000Source | 420,000,000Source | 403,900,000Source |
| Other Assets, NoncurrentUSD | 729,700,000Source | 631,400,000Source | 754,600,000Source | 637,700,000Source | 681,500,000Source | 777,500,000Source | 559,100,000Source | 697,600,000Source | 750,600,000Source | 560,500,000Source | 745,000,000Source | 1,529,200,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 11,000,000,000Source | 11,954,300,000Source | 13,713,500,000Source | 10,696,200,000Source | 10,915,000,000Source | 10,831,400,000Source | 11,054,400,000Source | 11,354,600,000Source | 11,182,700,000Source | 11,333,300,000Source | 12,045,400,000Source | 11,165,700,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | — | — | — | 100,000Source |
| Additional Paid in CapitalUSD | 797,700,000Source | 488,500,000Source | 242,200,000Source | 714,000,000Source | 407,500,000Source | 896,700,000Source | 629,900,000Source | 329,500,000Source | 863,100,000Source | 569,400,000Source | 302,500,000Source | 73,300,000Source |
| Retained Earnings (Accumulated Deficit)USD | 20,601,600,000Source | 18,993,100,000Source | 17,377,900,000Source | 20,135,100,000Source | 18,604,600,000Source | 20,872,200,000Source | 19,500,300,000Source | 18,021,000,000Source | 20,552,700,000Source | 19,259,800,000Source | 17,627,600,000Source | 16,466,500,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -214,800,000Source | -145,700,000Source | -159,300,000Source | -238,100,000Source | -146,000,000Source | -140,200,000Source | -174,500,000Source | -160,500,000Source | -182,000,000Source | -136,200,000Source | -153,700,000Source | -164,900,000Source |
| Stockholders' Equity Attributable to ParentUSD | — | — | 14,483,800,000Source | — | — | — | — | — | — | — | 14,799,400,000Source | 13,397,900,000Source |
| Liabilities and EquityUSD | 29,207,500,000Source | 28,313,200,000Source | 28,193,200,000Source | 28,330,200,000Source | 26,804,100,000Source | 29,483,100,000Source | 28,033,100,000Source | 26,567,600,000Source | 29,439,500,000Source | 28,049,300,000Source | 26,844,800,000Source | 24,554,100,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,290,000,000Source | 5,425,000,000Source | 5,022,300,000Source | 3,183,700,000Source | 3,108,200,000Source | 2,998,900,000Source | 5,297,400,000Source | 3,222,800,000Source | 3,349,400,000Source | 5,528,800,000Source | 3,434,300,000Source | 3,272,800,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 80,400,000Source | 86,400,000Source | 90,300,000Source | 97,200,000Source |
| Accounts Payable, CurrentUSD | 413,100,000Source | 422,700,000Source | 440,100,000Source | 408,400,000Source | 354,500,000Source | 358,500,000Source | 391,500,000Source | 387,000,000Source | 432,000,000Source | 424,200,000Source | 403,300,000Source | 491,500,000Source |
| Operating Lease, Liability, NoncurrentUSD | 305,000,000Source | 357,000,000Source | 428,800,000Source | 310,900,000Source | 367,500,000Source | 273,400,000Source | 323,400,000Source | 406,500,000Source | 290,400,000Source | 334,500,000Source | 400,000,000Source | 333,000,000Source |
| Deferred Income Tax Liabilities, NetUSD | 358,100,000Source | 882,400,000Source | 728,100,000Source | 118,300,000Source | 590,600,000Source | 483,500,000Source | 133,200,000Source | 658,100,000Source | 507,600,000Source | 190,500,000Source | 641,800,000Source | 334,700,000Source |
| Other Liabilities, NoncurrentUSD | 761,800,000Source | 744,100,000Source | 747,900,000Source | 799,600,000Source | 556,700,000Source | 787,100,000Source | 751,700,000Source | 777,100,000Source | 748,500,000Source | 732,300,000Source | 781,100,000Source | 944,200,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | -4,100,000Source | — | — | — | — | — | — | — | 0Source | -9,500,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 2,520,200,000Source | 2,799,300,000Source | 2,645,500,000Source | 1,696,600,000Source |
| Long-term DebtUSD | 6,285,100,000Source | 4,545,800,000Source | 6,786,400,000Source | 6,283,700,000Source | 6,292,000,000Source | 6,288,500,000Source | 4,548,700,000Source | 6,290,100,000Source | 6,286,800,000Source | 6,295,800,000Source | 6,938,200,000Source | 6,281,000,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 466,500,000Source | 388,500,000Source | 634,800,000Source | 583,600,000Source | 319,500,000Source | 240,500,000Source | 1,292,900,000Source | 1,632,200,000Source | 1,161,500,000Source | 2,961,600,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 204,400,000Source | 183,200,000Source | 779,900,000Source | 673,200,000Source | 494,800,000Source | 518,400,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 84,000,000Source | 81,000,000Source | 290,800,000Source | 291,200,000Source | 264,200,000Source | 254,100,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | -102,700,000Source | -222,300,000Source | -61,300,000Source | 203,400,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -116,200,000Source | -62,000,000Source | 64,700,000Source | 273,800,000Source | 130,900,000Source | 320,200,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 23,600,000Source | -27,800,000Source | 361,600,000Source | -158,100,000Source | -305,800,000Source | -168,600,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 645,500,000Source | 259,300,000Source | 2,204,600,000Source | 2,875,500,000Source | 1,547,200,000Source | 1,384,300,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | 1,074,800,000Source | 6,926,100,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -209,500,000Source | -47,300,000Source | -1,371,100,000Source | -799,200,000Source | -4,101,000,000Source | 1,576,600,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | 200,000Source | 200,000Source | -42,900,000Source | 4,700,000Source | 11,300,000Source | -24,400,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 51,200,000Source | 37,100,000Source | 153,800,000Source | 153,700,000Source | 277,000,000Source | 240,300,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 55,100,000Source | 24,300,000Source | 10,000,000Source | 31,300,000Source | 44,300,000Source | 1,900,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 750,000,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -43,800,000Source | -23,000,000Source | -301,900,000Source | -683,500,000Source | 149,300,000Source | -1,747,300,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | 11,300,000Source | 1,300,000Source | 5,000,000Source | -2,200,000Source | -6,000,000Source | -5,600,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | 0Source | 1,750,000,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,862,800,000Source | 1,699,200,000Source | 2,758,800,000Source | 1,908,900,000Source | 3,382,700,000Source | 2,598,300,000Source | 3,008,500,000Source | 2,375,000,000Source | 1,049,900,000Source | 3,419,300,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 264,100,000Source | 245,400,000Source | 252,200,000Source | 262,500,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 864,000,000Source | 355,100,000Source | 740,700,000Source | 932,900,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -18,000,000Source | 34,300,000Source | 101,900,000Source | -67,700,000Source | 35,100,000Source | -55,700,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | -75,000,000Source | — | -72,900,000Source | — | — | — | -301,500,000Source | -274,400,000Source | -263,500,000Source |
| Amortization of Intangible AssetsUSD | — | — | 135,700,000Source | 110,100,000Source | 127,400,000Source | 86,900,000Source | — | — | 507,100,000Source | 386,500,000Source | 240,600,000Source | 246,300,000Source |
| DepreciationUSD | — | — | 66,500,000Source | 72,700,000Source | 66,900,000Source | 71,900,000Source | 67,900,000Source | 71,400,000Source | 272,800,000Source | 286,700,000Source | 254,200,000Source | 272,400,000Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 1,505,400,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 3,800,000Source | -39,100,000Source | -5,300,000Source | 30,400,000Source | -22,300,000Source | 35,600,000Source | 19,700,000Source | 100,400,000Source | 275,200,000Source | 264,700,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 7,000,000Source | -10,900,000Source | 0Source | 600,000Source | -3,200,000Source | -5,400,000Source | 1,500,000Source | -2,000,000Source | 5,200,000Source | 0Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | -3,200,000Source | -28,200,000Source | -5,300,000Source | 29,800,000Source | -19,100,000Source | 41,000,000Source | 18,200,000Source | 102,400,000Source | 270,000,000Source | 264,700,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -10,300,000Source | -4,900,000Source | -10,400,000Source | -11,300,000Source | -6,500,000Source | 3,800,000Source | 28,600,000Source | 30,900,000Source | 50,400,000Source | 35,500,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | 0Source | 0Source | 0Source | 88,600,000Source | — | — | 0Source | 88,600,000Source | — | — |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | 19,700,000Source | 100,400,000Source | 291,200,000Source | 277,300,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 503,700,000Source |
| GoodwillUSD | — | — | 6,490,700,000Source | 6,485,800,000Source | 6,493,100,000Source | 6,227,400,000Source | 6,488,700,000Source | 6,477,100,000Source | 6,491,100,000Source | 6,478,900,000Source | 6,219,200,000Source | 5,749,000,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 7,900,000Source | 60,200,000Source | 0Source | 119,600,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 0Source | 20,200,000Source | 3,500,000Source | 0Source | 0Source | 0Source | 7,900,000Source | 40,000,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 2,600,000Source |
| Income Tax Expense (Benefit)USD | — | — | 90,800,000Source | 62,500,000Source | 109,200,000Source | 115,100,000Source | 58,200,000Source | 70,700,000Source | 263,600,000Source | 273,800,000Source | 135,300,000Source | 632,800,000Source |
| Inventory Write-downUSD | — | — | — | — | — | — | 4,800,000Source | 7,300,000Source | 29,200,000Source | 101,900,000Source | 124,400,000Source | 336,200,000Source |
| Investment Income, InterestUSD | — | — | 31,600,000Source | 11,600,000Source | 32,300,000Source | 20,100,000Source | 37,900,000Source | 23,900,000Source | 125,000,000Source | 67,600,000Source | 276,500,000Source | 89,300,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 466,500,000Source | 388,500,000Source | 634,800,000Source | 583,600,000Source | 319,500,000Source | 240,500,000Source | 1,292,900,000Source | 1,632,200,000Source | 1,161,100,000Source | 3,046,900,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source | — | 0Source | — | — | 0Source | 0Source | 400,000Source | -85,300,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -305,600,000Source | -343,600,000Source | -315,500,000Source | 108,200,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 52,900,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 15,800,000Source | -800,000Source | -3,300,000Source | -2,000,000Source | -1,100,000Source | 2,500,000Source | -24,700,000Source | 29,600,000Source | 3,500,000Source | 10,100,000Source |
| Pension Cost (Reversal of Cost)USD | — | — | — | — | — | — | — | — | 16,800,000Source | 17,500,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 1,733,100,000Source | 0Source | 997,200,000Source | 0Source |
| Proceeds from (Payments to) Noncontrolling InterestsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 12,300,000Source | 12,400,000Source |
| Other Operating Income (Expense), Net | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Realized Investment Gains (Losses) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Unrealized Gain (Loss) on Derivatives | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 2,534,700,000Source | 2,465,800,000Source | 2,645,500,000Source | 2,464,900,000Source | 2,477,800,000Source | 2,431,000,000Source | 9,890,600,000Source | 9,675,900,000Source | 9,835,600,000Source | 10,173,400,000Source |
| Cost of RevenueUSD | — | — | 674,400,000Source | 638,700,000Source | 605,000,000Source | 546,000,000Source | 661,000,000Source | 629,300,000Source | 2,404,200,000Source | 2,310,400,000Source | 2,533,400,000Source | 2,278,300,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 594,800,000Source | 588,400,000Source | 583,800,000Source | 553,800,000Source | 607,300,000Source | 572,500,000Source | 2,433,600,000Source | 2,403,700,000Source | 2,549,700,000Source | 2,403,600,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 15,800,000Source | -800,000Source | -3,300,000Source | -2,000,000Source | -1,100,000Source | 2,500,000Source | -24,700,000Source | 29,600,000Source | 3,500,000Source | 10,100,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 557,300,000Source | 451,000,000Source | 744,000,000Source | 698,700,000Source | 377,700,000Source | 311,200,000Source | 1,556,500,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 90,800,000Source | 62,500,000Source | 109,200,000Source | 115,100,000Source | 58,200,000Source | 70,700,000Source | 263,600,000Source | 273,800,000Source | 135,300,000Source | 632,800,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source | — | 0Source | — | — | 0Source | 0Source | 400,000Source | -85,300,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 466,500,000Source | 388,500,000Source | 634,800,000Source | 583,600,000Source | 319,500,000Source | 240,500,000Source | 1,292,900,000Source | 1,632,200,000Source | 1,161,100,000Source | 3,046,900,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 3.18Source | 2.67Source | 4.33Source | 4.01Source | 2.17Source | 1.65Source | 8.83Source | 11.21Source | 8.02Source | 20.96Source |
| Earnings Per Share, DilutedUSD per share | — | — | 3.17Source | 2.66Source | 4.33Source | 4Source | 2.15Source | 1.64Source | 8.79Source | 11.18Source | 7.97Source | 20.87Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 146,600,000Source | 145,700,000Source | 146,500,000Source | 145,600,000Source | 147,200,000Source | 146,100,000Source | 146,500,000Source | 145,600,000Source | 144,700,000Source | 145,300,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 147,100,000Source | 146,100,000Source | 146,700,000Source | 145,900,000Source | 148,400,000Source | 146,600,000Source | 147,100,000Source | 145,900,000Source | 145,600,000Source | 146,000,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 135,700,000Source | 110,100,000Source | 127,400,000Source | 86,900,000Source | — | — | 507,100,000Source | 386,500,000Source | 240,600,000Source | 246,300,000Source |
| Costs and ExpensesUSD | — | — | 1,977,400,000Source | 2,014,800,000Source | 1,901,500,000Source | 1,766,200,000Source | 2,100,100,000Source | 2,119,800,000Source | 8,334,100,000Source | 7,769,900,000Source | 8,538,800,000Source | 6,581,600,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -98,000,000Source | 431,900,000Source | 441,100,000Source | 801,400,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 7,000,000Source | -10,900,000Source | 0Source | 600,000Source | -3,200,000Source | -5,400,000Source | 1,500,000Source | -2,000,000Source | 5,200,000Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -10,300,000Source | -4,900,000Source | -10,400,000Source | -11,300,000Source | -6,500,000Source | 3,800,000Source | 28,600,000Source | 30,900,000Source | 50,400,000Source | 35,500,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 1,225,200,000Source | 853,400,000Source | 192,400,000Source | 1,842,000,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 2,600,000Source |
| Interest ExpenseUSD | — | — | 67,400,000Source | 59,800,000Source | 72,600,000Source | 61,300,000Source | 67,600,000Source | 60,000,000Source | 267,500,000Source | 250,300,000Source | 246,900,000Source | 246,600,000Source |
| Investment Income, InterestUSD | — | — | 31,600,000Source | 11,600,000Source | 32,300,000Source | 20,100,000Source | 37,900,000Source | 23,900,000Source | 125,000,000Source | 67,600,000Source | 276,500,000Source | 89,300,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -305,600,000Source | -343,600,000Source | -315,500,000Source | 108,200,000Source |
| Other Operating Income (Expense), Net | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Realized Investment Gains (Losses) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
d109852dex991.htm · 8-K · 2026-05-14
EX-99.1 4 d109852dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Biogen Completes Acquisition of Apellis Pharmaceuticals Cambridge, Mass. - May 14, 2026 - Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen. The acquisition adds two best-in-class commercialized products, EMPAVELI® and SYF…
Read attachment ↗ex99-1.htm · SC TO-C · 2026-04-07
Exhibit 99.1 Presentation at Apellis Pharmaceuticals, Inc. Employee Meeting on April 7, 2026 C OMBINING OUR STRENGTHS GETTING TO KNOW BIOGEN Confidential - For Internal Integration Planning Purposes Only Important Information The tender offer described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any Apellis Common Stock or any other securities, nor is it a substitu…
Read attachment ↗ex99-1.htm · SC TO-C · 2026-04-03
Exhibit 99.1 Exhibit 99.1 LinkedIn: The following communication was posted by Biogen Inc. (the “Company”) on LinkedIn on March 31, 2026. Frame 1: Biogen DEAL NEWS Biogen announces definitive agreement to acquire Apellis Today we announced that we have entered into a definitive agreement to acquire Apellis Pharmaceuticals. We believe this potential acquisition will enhance our growth portfolio in immunology medicines and accelerate our entry into nephrology. Learn more about the deal: https:…
Read attachment ↗d14986dex991.htm · 8-K · 2026-03-31
EX-99.1 3 d14986dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of March 31, 2026, is by and among Biogen Inc., a Delaware corporation (“Parent”), Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and each stockholder listed on the signature pages hereto (each, a “Stockholder”). WHEREAS, each Stockholder is, as of the date hereof, the record or benefi…
Read attachment ↗d14986dex992.htm · 8-K · 2026-03-31
EX-99.2 4 d14986dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal disease Brin…
Read attachment ↗ex99-2.htm · SC TO-C · 2026-03-31
Exhibit 99.2 31-Mar-2026 Biogen, Inc. (BIIB) Business Update Call CORPORATE PARTICIPANTS Timothy Power Head-Investor Relations, Biogen, Inc. Christopher A. Viehbacher President, Chief Executive Officer & Director, Biogen, Inc. Adam Keeney Executive Vice President & Head-Corporate Development, Biogen, Inc. Robin C. Kramer Executive Vice President & Chief Financial Officer, Biogen, Inc. Alisha A. Alaimo President, Head-North America & Board Member-Biogen Foundation, Biogen, Inc. Pri…
Read attachment ↗